Full-Time
Icon
10,001+ employees
Consulting and development services for pharmaceuticals
No salary listed
Mid, Senior
Company Does Not Provide H1B Sponsorship
Remote in USA
Home-based in the U.S.
Get referrals →
You have ways to get a Icon referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 4 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Bachelor's degree in a scientific or healthcare-related field.
- Minimum of 2 years of independent monitoring experience.
- In-depth knowledge of clinical trial processes, regulations, and ICH-GCP guidelines.
- Strong organizational and communication skills, with attention to detail.
- Ability to work independently and collaboratively in a fast-paced environment.
- Conducting site qualification, initiation, monitoring, and close-out visits for clinical trials.
- Ensuring protocol compliance, data integrity, and patient safety throughout the trial process.
- Collaborating with investigators and site staff to facilitate smooth study conduct.
- Performing data review and resolution of queries to maintain high-quality clinical data.
- Contributing to the preparation and review of study documentation, including protocols and clinical study reports.
- Experience monitoring Oncology, Obesity, and/or Gastrointestinal studies preferred.
Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon has a global team of experts who specialize in various therapeutic areas, allowing them to offer tailored solutions that meet the specific needs of their clients. The company's goal is to support the development of life-saving products and improve the overall quality of life for patients.
Company Size
10,001+
Company Stage
IPO
Headquarters
Ireland
Founded
1990
Simplify's Take
What believers are saying
- Partnership with Mural Health enhances trial participant management and engagement.
- Increased AI use in biomarker detection boosts ICON's neurodegenerative research capabilities.
- Barry Balfe's appointment as COO strengthens ICON's operational excellence and growth potential.
What critics are saying
- Securities fraud lawsuit poses financial and reputational risks for ICON.
- Complexity in multi-indication trials may lead to inefficiencies in clinical development.
- Underutilization of biomarkers in trials could hinder ICON's research efficiency.
What makes Icon unique
- ICON's global network spans 53 countries, offering comprehensive clinical research services.
- Focus on reducing time to market, cost, and increasing quality sets ICON apart.
- ICON's expertise in multi-indication studies enhances its competitive edge in clinical trials.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
401(k) Retirement Plan
Mental Health Support
Life Insurance
Flexible Work Hours
Company News
Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.
Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process
After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.
ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.
The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).